<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Anargyrou, K.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Vassilakopoulos, T.P.</style></author><author><style face="normal" font="default" size="100%">Pouli, A.</style></author><author><style face="normal" font="default" size="100%">Sachanas, S.</style></author><author><style face="normal" font="default" size="100%">Tzenou, T.</style></author><author><style face="normal" font="default" size="100%">Masouridis, S.</style></author><author><style face="normal" font="default" size="100%">Christoulas, D.</style></author><author><style face="normal" font="default" size="100%">Angelopoulou, M.K.</style></author><author><style face="normal" font="default" size="100%">Dimitriadou, E.M.</style></author><author><style face="normal" font="default" size="100%">Kalpadakis, C.</style></author><author><style face="normal" font="default" size="100%">Tsionos, K.</style></author><author><style face="normal" font="default" size="100%">Panayiotidis, P.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Pangalis, G.A.</style></author><author><style face="normal" font="default" size="100%">Kyrtsonis, M.-C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib</style></title><secondary-title><style face="normal" font="default" size="100%">Haematologica</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">bortezomib</style></keyword><keyword><style  face="normal" font="default" size="100%">myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">Serum Ang-1/Ang-2 ratio</style></keyword><keyword><style  face="normal" font="default" size="100%">Serum angiopoietins</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-40849146069&amp;doi=10.3324%2fhaematol.11852&amp;partnerID=40&amp;md5=469d8cdec52714daeeecf22801d5a7bd</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">93</style></volume><pages><style face="normal" font="default" size="100%">451 - 454</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Neoangiogenesis is involved in the pathophysiology of multiple myeloma and angiopoietins possibly contribute to myeloma-induced neovascularization. Bortezomib's antineoplastic potential includes an anti-angiogenic effect. We determined serum levels of angiopoietin-1 and angiopoietin-2 with ELISA pre- and post-bortezomib administration in 35 patients with relapsed/refractory multiple myeloma. Pre-bortezomib, serum angiopoietin-1 levels did not differ in patients and in healthy individuals, while serum angiopoietin-2 levels were elevated. Corresponding serum angiopoietin-1/angiopoietin-2 ratio was reduced in patients compared with controls. After treatment, serum angiopoietin-1 levels increased, while serum angiopoietin-2 levels decreased, therefore the angiopoietin-1/ angiopoietin-2 ratio increased and normalized. This increase was significant in patients who responded to treatment. In conclusion, angiopoietin-1/angiopoietin- 2 ratio normalization reflected response to bortezomib. ©2008 Ferrata Storti Foundation.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><notes><style face="normal" font="default" size="100%">Cited By :20Export Date: 21 February 2017</style></notes></record></records></xml>